Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
988 participants
INTERVENTIONAL
1996-11-30
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Both treatments are equally effective at preventing death and subsequent myocardial infarction and most doctors are happy to recommend either option. Angioplasty offers a more simple initial procedure but with a chance of needing a repeat performance. Bypass surgery represents a more significant initial undertaking with a longer recovery and convalescent period but in most cases, provides good relief of symptoms. Patient preference plays an important part in the decision process.
Bypass grafting is currently the therapy most frequently performed world-wide. Angioplasty has a number of important advantages but the need for repeat procedures currently limits its appeal.
Since these trials were performed there have been important advances in angioplasty techniques. Prominent amongst these has been the development and use of Coronary Stents which has been shown (in clinical trials) to reduce the need for repeat procedures after an initial angioplasty. Consequently stent implantation is now in routine use world wide.
If angioplasty is performed with coronary stent implantation then this may reduce the need for repeat procedures and address the principal factor currently limiting the value of this approach. If the results were found to be as good as with bypass grafting then patients could benefit from a shorter hospital stay, a less traumatic operation and a shorter recovery period. We therefore wish to compare the outcomes in patients treated with a) bypass grafting or b) angioplasty with coronary stent implantation.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
percutaneous coronary intervention
coronary artery bypass grafting
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has typical angina pectoris - stable or unstable symptoms.
* Atherosclerotic coronary artery disease demonstrated with selective coronary angiography with a significant lesion present in at least two of the principal epicardial vessel systems.
* Revascularisation procedure clinically indicated.
* Nominated trial surgeon accepts the patient for CABG.
* Nominated trial interventionist accepts the patient for PTCA and stent.
* At least one identified lesion suitable and targeted for primary stent implantation.
* A procedure for the completion of either revascularisation strategy can be performed within 6 weeks of randomisation.
Exclusion Criteria
* Previous coronary interventional procedure (of any type).
* Intervention on any cardiac valve scheduled for the index revascularisation procedure.
* Excision or other intervention on the myocardium scheduled for the index revascularisation procedure.
* Intervention on the great vessels, carotid arteries or aorta scheduled for the index revascularisation procedure.
* Absent autologous graft material.
* Non-cardiac disease influencing survival.
* Acute myocardial infarction in the 48 hours preceding the proposed revascularisation procedure.
* Participation in any other study that would involve deviation from the routine local management of a revascularisation procedure.
* Allergy to anti-platelet agents in local use.
* Language or other communication barrier.
* Follow-up for two years not possible / Patient unreliable.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
Guidant Corporation
INDUSTRY
Schneider
UNKNOWN
British Heart Foundation
OTHER
Royal Brompton & Harefield NHS Foundation Trust
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodney H Stables
Role: STUDY_CHAIR
Liverpool Cardiothoracic Centre
Ulrich Sigwart
Role: STUDY_CHAIR
University Hospital, Geneva
Spencer King
Role: PRINCIPAL_INVESTIGATOR
Fuqua Heart Centre of Atlanta Piedmont Hospital
John Pepper
Role: PRINCIPAL_INVESTIGATOR
Royal Brompton & Harefield NHS Foundation Trust
Peter Wahrborg
Role: PRINCIPAL_INVESTIGATOR
Institute of Stress Medicine
William Weintraub
Role: PRINCIPAL_INVESTIGATOR
Christiana Centre for Outcomes Research
Jacobus Lubsen
Role: PRINCIPAL_INVESTIGATOR
Erasmus Medical Centre Rotterdam
Petros Nihoyannopolous
Role: PRINCIPAL_INVESTIGATOR
Hammersmith Hospitals NHS Trust
References
Explore related publications, articles, or registry entries linked to this study.
Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, Stables RH; SoS Investigators. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation. 2008 Jul 22;118(4):381-8. doi: 10.1161/CIRCULATIONAHA.107.739144. Epub 2008 Jul 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MREC/98/2/123
Identifier Type: -
Identifier Source: org_study_id